EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Cardiovascular Outcomes Among Patients with COPD Prescribed with LABA or LAMA: A Real-World Territory Wide Study

Chun Ka Wong, Eugene C C Cheng, Ali Choo, Chung Ki Tsui, Audrey Tsznam Ko, Ting Fung Ma, Hung-Fat Tse, James Chung Man Ho, Wang Chun Kwok

Advances in Therapy · 2025-12 · 42 (12) · 6163-6174

DOI: 10.1007/s12325-025-03375-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Advances in Therapy, online erschienen am 18.10.2025. Verfasst von Chun Ka Wong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Cardiology Division, Department of Medicine, School of Clinical Medicine, Li Ka Shing, The University of Hong Kong, Hong Kong SA…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Adrenergic beta-Agonists, Muscarinic Antagonists, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This study aims to compare cardiovascular outcomes among patients who received long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) and thereby better inform the choice of pharmacotherapy prescription for patients with chronic obstructive pulmonary disease (COPD). METHOD: A real-world territory-wide retrospective cohort study using electronic data patient databases in Hong Kong was conducted. Patients with COPD without cardiovascular disease who were new users of LABA or LAMA from public hospitals in Hong Kong between 2010 and 2019 were identified and were followed up for 3 years after treatment initiation. Incidences of cardiovascular events were compared. Propensity score matching was employed to match important patient characteristics and clinical features. RESULTS: After the propensity score matching, 5020 patients were included: 2510 treated with LABA and 2510 with LAMA. At 3-year follow-up, 19.6% of patients experienced cardiovascular events. LAMA treatment was associated with a higher incidence of cardiovascular events compared to LABA (20.2% vs 19.0%, adjusted hazard ratio [aHR] 1.14, p = 0.04). This difference was primarily driven by increased risks of new-onset atrial fibrillation (7.93% vs 6.53%, aHR 1.30, p = 0.01). Incidence rates were similar between groups for ventricular tachycardia and fibrillation (0.52% vs 0.80%, p = 0.32), acute coronary syndrome (4.06% vs 3.82%, p = 0.33), ischemic stroke (2.39% vs 2.59%, p = 0.98), and heart failure hospitalization (10.8% vs 9.84%, p = 0.05). CONCLUSION: Patients with COPD treated with LAMA might have higher incidence of atrial fibrillation when compared with LABA but not other cardiovascular events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveAdrenergic beta-AgonistsMuscarinic AntagonistsCardiovascular DiseasesBronchodilator AgentsRetrospective StudiesHong KongIncidencePropensity ScoreFollow-Up StudiesHospitalizationHumansMaleFemaleMiddle AgedAgedAged, 80 and over

Stichwörter der Autor:innen

ArrhythmiaAtrial fibrillationCOPDLABALAMA

Substanzen

Adrenergic beta-AgonistsMuscarinic AntagonistsBronchodilator Agents

Autor:innen und Institutionen

  • Faculty of Medicine, Cardiology Division, Department of Medicine, School of Clinical Medicine, Li Ka Shing, The University of Hong Kong, Hong Kong SAR, China.
  • Faculty of Medicine, Respiratory Medicine Division, Department of Medicine, School of Clinical Medicine, Li Ka Shing, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China.
  • Department of Statistics, College of Arts and Sciences, University of South Carolina, Columbia, SC, 29208, USA.
  • Faculty of Medicine, Respiratory Medicine Division, Department of Medicine, School of Clinical Medicine, Li Ka Shing, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China. kwokwch@hk…

Zitieren

APA

Wong, C. K., Cheng, E. C. C., Choo, A., Tsui, C. K., Ko, A. T., Ma, T. F., Tse, H. F., Ho, J. C. M., & Kwok, W. C. (2025). Cardiovascular Outcomes Among Patients with COPD Prescribed with LABA or LAMA: A Real-World Territory Wide Study. Advances in Therapy, 42(12), 6163-6174. https://doi.org/10.1007/s12325-025-03375-5

Vancouver

Wong CK, Cheng ECC, Choo A, Tsui CK, Ko AT, Ma TF, et al. Cardiovascular Outcomes Among Patients with COPD Prescribed with LABA or LAMA: A Real-World Territory Wide Study. Advances in Therapy. 2025;42(12):6163-6174. doi:10.1007/s12325-025-03375-5

BibTeX
@article{Wong2025,
  author = {Wong, Chun Ka and Cheng, Eugene C C and Choo, Ali and Tsui, Chung Ki and Ko, Audrey Tsznam and Ma, Ting Fung and Tse, Hung-Fat and Ho, James Chung Man and Kwok, Wang Chun},
  title = {Cardiovascular Outcomes Among Patients with COPD Prescribed with LABA or LAMA: A Real-World Territory Wide Study},
  journal = {Advances in Therapy},
  year = {2025},
  volume = {42},
  number = {12},
  pages = {6163--6174},
  doi = {10.1007/s12325-025-03375-5}
}
Kostenlos starten →